Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
Colorcon
Dow
AstraZeneca
Baxter

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Teriparatide recombinant human - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for teriparatide recombinant human and what is the scope of freedom to operate?

Teriparatide recombinant human is the generic ingredient in one branded drug marketed by Lilly and is included in one NDA. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Teriparatide recombinant human has ninety-eight patent family members in thirty-seven countries.

There are four drug master file entries for teriparatide recombinant human. One supplier is listed for this compound.

Recent Clinical Trials for teriparatide recombinant human

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of California, San FranciscoPhase 4
VA Office of Research and DevelopmentPhase 4
The University of Hong KongN/A

See all teriparatide recombinant human clinical trials

Recent Litigation for teriparatide recombinant human

Identify potential future generic entrants

District Court Litigation
Case NameDate
Eli Lilly and Company v. Apotex, Inc.2018-04-05
ELI LILLY AND COMPANY v. TEVA PHARMACEUTICALS USA, INC.2016-03-16

See all teriparatide recombinant human litigation

Pharmacology for teriparatide recombinant human
Paragraph IV (Patent) Challenges for TERIPARATIDE RECOMBINANT HUMAN
Tradename Dosage Ingredient NDA Submissiondate
FORTEO INJECTABLE;SUBCUTANEOUS teriparatide recombinant human 021318 2015-07-27

US Patents and Regulatory Information for teriparatide recombinant human

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No   Start Trial   Start Trial   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002 DISCN No No   Start Trial   Start Trial Y   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for teriparatide recombinant human

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002   Start Trial   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002   Start Trial   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008   Start Trial   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-001 Nov 26, 2002   Start Trial   Start Trial
Lilly FORTEO teriparatide recombinant human INJECTABLE;SUBCUTANEOUS 021318-002 Jun 25, 2008   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Mallinckrodt
Medtronic
Express Scripts
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.